GH Research PLC (NASDAQ:GHRS) Given Average Rating of “Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $30.86.

Several brokerages have recently commented on GHRS. Royal Bank of Canada started coverage on shares of GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price on the stock. Stifel Nicolaus boosted their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Monday, January 27th. Cantor Fitzgerald assumed coverage on shares of GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 target price for the company. Finally, Guggenheim began coverage on GH Research in a research report on Thursday, March 13th. They set a “buy” rating and a $32.00 price target on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GHRS. Geode Capital Management LLC increased its stake in shares of GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after buying an additional 3,092 shares during the period. AdvisorShares Investments LLC increased its position in GH Research by 15.4% in the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after purchasing an additional 4,806 shares during the period. BNP Paribas Financial Markets bought a new stake in GH Research during the 4th quarter worth about $44,000. Northern Trust Corp lifted its position in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the period. Finally, Palumbo Wealth Management LLC bought a new position in shares of GH Research in the 1st quarter valued at about $142,000. Institutional investors own 56.90% of the company’s stock.

GH Research Stock Up 0.3 %

Shares of GHRS opened at $9.53 on Friday. The company has a 50-day moving average price of $10.54 and a two-hundred day moving average price of $9.65. The stock has a market cap of $495.83 million, a price-to-earnings ratio of -12.06 and a beta of 0.84. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. Equities research analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).